Last reviewed · How we verify
Fractional IPV( fIPV)
Fractional IPV (fIPV) is a reduced-dose inactivated polio vaccine that provides immunological protection against poliovirus while using a smaller antigen quantity per dose.
Fractional IPV (fIPV) is a reduced-dose inactivated polio vaccine that provides immunological protection against poliovirus while using a smaller antigen quantity per dose. Used for Poliomyelitis prevention in infants and children.
At a glance
| Generic name | Fractional IPV( fIPV) |
|---|---|
| Sponsor | International Centre for Diarrhoeal Disease Research, Bangladesh |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
fIPV contains the same inactivated poliovirus antigens as standard IPV but at one-fifth the standard dose, administered intradermally or as a fractional dose. This approach maintains immunogenicity while reducing antigen requirements, making it suitable for resource-limited settings and contributing to polio eradication efforts by stretching vaccine supply.
Approved indications
- Poliomyelitis prevention in infants and children
Common side effects
- Local injection site reactions (pain, redness, swelling)
- Fever
- Irritability
Key clinical trials
- Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV) (PHASE4)
- Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT (PHASE1)
- Immunogenicity of Intramuscular and Intradermal IPV (PHASE4)
- Assessment of Poliovirus Type 2 Immunogenicity of One and Two Dose Schedule With IPV and fIPV When Administered at 9-13 Months of Age in Bangladesh (PHASE4)
- Monovalent Oral Poliovirus Vaccine Type 1 Intestinal and Humoral Immunity Study (PHASE4)
- Use of mOPV1 in Routine Immunization in Pakistan. (NA)
- Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant (PHASE1)
- Comparison of Immunity Following IPV Versus fIPV: a Community Based Randomized Controlled Trial in Pakistan (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: